This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Sodium alginate with magnesium alginate

Updated 2 Feb 2023 | Alginate preparations


Oral powder containing sodium alginate 225mg and magnesium alginate 87.5mg (equivalent to 1 unit dose sachet)

Drugs List

  • Therapeutic Indications


    Indicated for gastric regurgitation, gastro-oesophageal reflux and reflux associated with hiatus hernia in infants and young children.



    Children aged under 2 years

    Breast fed infants
    Under 4.5kg - one sachet.
    Over 4.5kg - two sachets.

    Put the required dose into a glass and add 5ml of cooled, boiled water. Mix to a smooth paste and add another 10ml water and mix. Give part way through each feed or meal using a spoon or feeding bottle.

    Bottle fed infants
    Under 4.5kg - one sachet to be mixed into not less than 115ml of each feed in the bottle and shaken well.
    Over 4.5kg - two sachets to be mixed into not less than 230ml of each feed in the bottle and shaken well.

    Young children
    Two doses prepared as for breast fed infants to be taken after each meal.

    Treatment should not be administered more than 6 times in 24 hours.

    Not suitable for use in infants under 1 year unless under medical supervision.


    Gastro-oesophageal reflux disease (unlicensed)

    Under 4.5kg: 1 sachet as needed. Maximum 6 sachets per day.
    4.5kg and over: 2 sachets as needed. Maximum 12 sachets per day.

    Patients with Renal Impairment

    Contraindicated in infants with known or suspected renal impairment due to the sodium content (approximately 23.9mg or 1.04mmol per dose) that may add to the risk of hypernatraemia.


    For oral use.

    Mix immediately before use with water or milk feed.

    Do not use with other preparations containing thickening agents.


    Intestinal obstruction

    Treatment of infants with gastro-enteritis

    Impaired renal function (see 'Renal Impairment' section)

    Situations where excessive water loss is likely e.g. fever, diarrhoea, vomiting or high room temperature

    Precautions and Warnings

    Use with caution in conditions where restricted sodium intake is indicated.

    Hypernatraemia should be treated with oral fluids and the infant's electrolytes monitored. Hypo-osmotic solutions should be used to treat severe cases.

    Do not use with other preparations containing thickening agents.

    Not suitable for use in infants under 1 year unless under medical supervision.

    The infant's condition should be reviewed seven days after starting treatment or earlier if symptoms worsen.

    Pregnancy and Lactation


    Not applicable.


    Not applicable.

    Effects on Ability to Drive and Operate Machinery

    Not applicable.

    Side Effects

    Gastric distension


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Shelf Life and Storage

    Do not store above 30 degrees C.

    Further Information

    Last Full Review Date: March 2011

    Reference Sources

    Summary of Product Characteristics: Gaviscon Infant. Forum Health Product Limited. Revised February 2020.

    NICE Evidence Services Available at: Last accessed: 23 April 2021

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.